Merrimack Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, Restructuring
November 10, 2016 11:44 AM ESTBTIG affirms Merrimack Pharma (Nasdaq: MACK) at Neutral following Q3 results and announced restructuring.
Analyst Ling Wang commented, Q16 ONIVYDE net revenues of $14.5M slightly missed consensus ($16.6M) and our estimate ($16.7M). It ended 3Q16 with cash & equivalents of $48.5M. Management provided updated... More



